
About Zumutor Biologics
Zumutor Biologics is a Healthcare company based in Bengaluru (India) founded in 2013 by Kavitha Iyer Rodrigues. Zumutor Biologics is focused on developing novel immunotherapies. It operates on a HealthTech model. Zumutor Biologics has raised $35.19 million across 9 funding rounds from investors including Accel, Bharat Fund and Aarin Capital. The company has 23 employees. Its chief executive, as recorded, is Kavitha Iyer Rodrigues. Its Indian entity Zumutor Biologics Private Limited reported revenue of βΉ4.63 Cr. Zumutor Biologics offers products and services including ZM008 and Monoclonal Antibodies. Its focus areas include Biotechnology and Immuno-Oncology.
Company details
Zumutor Biologics is engaged in the discovery and development of novel drug products, particularly in the field of immuno-oncology. The company specializes in targeted NK cell therapeutics using proprietary human antibody platforms like INABLR. Headquartered in Cambridge, MA, USA, with RD facilities in Bangalore, India, Zumutor is involved in creating first-in-class therapeutic antibodies that address innate immunity and tumor microenvironments. Additionally, bespoke services are offered to facilitate partners discovery programs and co-development of monoclonal antibodies.
- Headquarters Bengaluru, India
- Employees 23
- Founders Kavitha Iyer Rodrigues
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website zumutor.com
- Social LinkedIn X Facebook
- Legal Name Zumutor Biologics Inc
- Date of Incorporation 31 Jul, 2015
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹4.63 Cr
FY 2025 · -64% YoY
- Net Loss-₹3.90 Cr
FY 2025 · -84% margin
- EBITDA-₹3.35 Cr
FY 2025 · -72% margin
- Total Equity Funding$35.19M (USD)
in 9 rounds
- Latest Funding Round$7.3M (USD), Series B
Jun 2026
- InvestorsAccel
& 10 more
- Employee Count23
Associated legal entities of Zumutor Biologics
Zumutor Biologics operates through Zumutor Biologics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zumutor Biologics Private Limited CIN U73200KA2015FTC081944 | Active | 31 Jul 2015 | Bangalore, Karnataka | ₹4.6 Cr | 23 | 5 | View details |
Products & Services of Zumutor Biologics
Zumutor Biologics offers a comprehensive portfolio of products and services, including ZM008 and Monoclonal Antibodies.
ZM008 is developed as an anti-LLT1 antibody therapy.
Monoclonal antibodies are created for targeted therapeutic solutions.
Funding Insights of Zumutor Biologics
Zumutor Biologics has successfully raised a total of $35.19M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $7.3 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.19M
- Total Rounds 9
- Last Round Series B β $7.3M
- First Round $6M
(Jun 2013)
- Investors Count 11
All 9 funding rounds of Zumutor Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $7.3M | Series B | β | β | |
| Nov 2024 | $730,410 | Series A | β | Siana Capital, Anand Suresh Deshpande | β |
| Feb 2024 | $720,265 | Series A | β | Bharat Innovation Fund | β |
| Oct 2022 | $241,344 | Series A | β | Siana Capital | β |
| Dec 2021 | $6.2M | Series A | β | Siana Capital, Accel | β |
| Nov 2019 | $4M | Series A | β | Bharat Innovation Fund | |
| Apr 2018 | $4M | Series A | β | Accel | β |
| Jun 2015 | $6M | Series A | β | β | β |
| Jun 2013 | $6M | Seed | β | Accel, Aarin Capital | β |
11 investors in total: 7 institutional and 4 angel.
Investors in Zumutor Biologics
Zumutor Biologics has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Accel, Bharat Fund and Aarin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture fund management focusing on deep tech and science investments in India. | 2018 | sianacapital.com | Bengaluru, India | |
Accel is recognized as a leading venture capital firm. | 1983 | accel.com | Palo Alto, United States | |
Funding for IP-driven deep-tech and digitization-led inclusive solutions. | 2017 | bharat.fund | Ahmedabad, India | |
Venture funding in technology-intensive businesses within healthcare, education, and India-centric markets. | 2012 | aarincapital.com | Bengaluru, India | |
Tech focused Venture Capital firm investing globally | idgventures.com | San Francisco, United States | ||
| premjiinvest.com | ||||
India focused VC fund | 1999 | kitven.com | Bengaluru, India | |
AS Anand Suresh Deshpande | unknown_9270509704ea48139 | |||
SS Sharad Sanghi | Founder of Netmagic Solutions, prominent angel investor in Indian tech startups | unknown_fbdf9f894e964ac4b | ||
BS B S Ajai Kumar | unknown_3ec3476ba9cf4b178 |
Investor details for Zumutor Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Zumutor Biologics Private Limited (Zumutor Biologics)
Zumutor Biologics Private Limited is the primary company behind Zumutor Biologics. The board of Zumutor Biologics Private Limited currently have 3 directors; the longest-serving is Maloy Ghosh, appointed in 2016. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Maloy Ghosh DIN 06402193 | Whole-time director | 01 Oct 2016 | 10 yrs 1 mo | Zumutor Biologics Private Limited |
| Kavitha Iyer Rodrigues DIN 01800241 | CEO | 01 Oct 2016 | 10 yrs 1 mo | Zumutor Biologics Private Limited |
| Ashwin Raguraman DIN 00879680 | Nominee Director | 26 Aug 2021 | 5 yrs 2 mo | Zumutor Biologics Private Limited |
People of Zumutor Biologics
14 people are tracked at Zumutor Biologics (3 in leadership, 11 in board & advisors); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO | Leadership | |
| Chief Scientific Officer | Leadership | |
Anirban Bhattacharya | CFO | Leadership |
Karthik Viswanathan | Scientific Board Member | Board & advisors |
Anurag Rathore | Scientific Board Member | Board & advisors |
Stephen Hodi | Scientific Board Member | Board & advisors |
Ana Anderson | Scientific Board Member | Board & advisors |
Narendra Chirmule | Scientific Board Member | Board & advisors |
Raghavan V | Scientific Board Member | Board & advisors |
Charles Cooney | Strategic Advisor | Board & advisors |
Mark Wolters | Strategic Advisor | Board & advisors |
Patrick Vink | Strategic Advisor | Board & advisors |
Andy Rakestraw | Scientific Board Member | Board & advisors |
Pradip Mazumdar | Scientific Board Member | Board & advisors |
Complete people profiles for Zumutor Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Zumutor Biologics
Figures of Zumutor Biologics Private Limited, the primary company behind Zumutor Biologics, for FY 2025. Revenue was ₹4.63 Cr (-64% year on year). Net loss was -₹3.90 Cr (-84% margin). EBITDA was -₹3.35 Cr (-72% margin). Revenue has grown at a compounded annual rate of -42% over three years and -21% over five years.
- ₹4.63 CrRevenue · FY 2025 · -64% YoY
- -₹3.90 CrNet loss · -84% margin
- -₹3.35 CrEBITDA · -72% margin
- ₹1.2 LakhPaid-up capital
- 23Employees (provident fund records)
- -42%Revenue CAGR, 3 years
- -21%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Zumutor Biologics Private Limited are on its company page.
Detailed financial statements for Zumutor Biologics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Zumutor Biologics
3 dated milestones of Zumutor Biologics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Zumutor Biologics is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series B, of $7.3M.
Web traffic of Zumutor Biologics
The website of Zumutor Biologics (zumutor.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 22.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zumutor Biologics
Complete news archive for Zumutor Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zumutor Biologics
Zumutor Biologics was founded in 2013.
Zumutor Biologics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Kavitha Iyer Rodrigues is the CEO of Zumutor Biologics, as recorded in our data. They have also founded this company.
Zumutor Biologics is a funded company, having raised a total of $35.19M across 9 funding rounds to date. The company's 1st funding round was a Seed of $6M, raised on Jun 2013.
Zumutor Biologics has 23 employees.
The primary company behind Zumutor Biologics, Zumutor Biologics Private Limited, reported revenue of βΉ4.63 Cr for FY 2025, down 64% year on year.
Zumutor Biologics is engaged in the discovery and development of novel drug products, particularly in the field of immuno-oncology. The company specializes in targeted NK cell therapeutics using proprietary human antibody platforms like INABLR. Headquartered in Cambridge, MA, USA, with RD facilities in Bangalore, India, Zumutor is involved in creating first-in-class therapeutic antibodies that address innate immunity and tumor microenvironments. Additionally, bespoke services are offered to facilitate partners discovery programs and co-development of monoclonal antibodies.
Zumutor Biologics offers ZM008 and Monoclonal Antibodies.
Zumutor Biologics has 11 investors. Key investors include Accel, Bharat Fund, Aarin Capital, Karnataka Information Technology Venture Capital Fund, and Siana Capital.
Zumutor Biologics operates through Zumutor Biologics Private Limited.
The legal entities of Zumutor Biologics currently have 4 directors, including Ashwin Raguraman, Maloy Ghosh, Kavitha Iyer Rodrigues and others.
